{"disease":{"id":"relapsed-ovarian-cancer","name":"relapsed ovarian cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05607329","title":"Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02983799","title":"Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02282020","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03705156","title":"Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":265,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03534453","title":"Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02825420","title":"Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"PharmaMar","has_results":true},{"nct_id":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":187,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT05479487","title":"Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Xiaohua Wu MD","has_results":false},{"nct_id":"NCT04152941","title":"Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"ARCAGY/ GINECO GROUP","has_results":false},{"nct_id":"NCT04517357","title":"A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04998760","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT05080556","title":"Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03323398","title":"Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT04887961","title":"Reprab Study: PLD + Trabectedin Rechallenge","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":64,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06081595","title":"Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Jin Li","has_results":false},{"nct_id":"NCT04861181","title":"NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT04999605","title":"A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Akeso","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}